Patent Grant
11260015
The present invention generally relates to injectable compositions and more specifically relates to hyaluronic acid-based compositions for treatment of fine lines in skin.
Current injectable treatment options for improving skin quality over the full-face or other significant surface area of skin require multiple treatment sessions (typically 3-4 treatments, every three to four weeks) and have a relatively short duration of effect.
Skin is composed of the epidermis and the dermis. The outermost epidermis is made up of stratified squamous epithelium with an underlying basement membrane. It contains no blood vessels, and is nourished by diffusion from the dermis. The main type of cells which make up the epidermis are keratinocytes, with melanocytes and langerhans cells being also present. This layer of skin is responsible for keeping water in the body and keeping harmful chemicals and pathogens out.
The dermis lies below the epidermis and contains a number of structures including blood vessels, nerves, hair follicles, smooth muscle, glands and lymphatic tissue. The dermis (or corium) is typically 3-5 mm thick and is the major component of human skin. It is composed of a network of connective tissue, predominantly collagen fibrils providing support and elastic tissue providing flexibility. The main cell types are fibroblasts, adipocytes (fat storage) and macrophages. Hyaluronic acid (HA) is a part of the dermis composition and is a major component of the extra cellular matrix.
Facial aging occurs as the result of several factors: inherent changes within the skin, effects of gravity, facial muscles acting on the skin (dynamic lines), soft tissue loss or shift and bone loss and loss of tissue elasticity. The skin ages when the epidermis begins to thin, causing the junction with the dermis to flatten. Collagen decreases as a person ages and the bundles of collagen, which gives the skin turgor, become looser and lose strength. When the skin loses elasticity, it is less able to resist stretching. Coupled with gravity, muscle pull and tissue changes, the skin begin to wrinkle. Water loss and breakdown of bonds between cells also reduces the barrier function of the skin, which can cause the skin's pore size to increases.
It is well known that the eyes are often the first facial feature to show signs of aging. Skin changes around the eyes occur earlier than in the rest of the face since the skin is thinner around the eyes. The skin here contains fewer glands and is subjected to constant blinking, squinting, rubbing, and pulling. The midface ages when the cheeks begin to droop, causing nasolabial folds. Nasolabial folds are the lines that run from the sides of the nose to the corners of the mouth. In the lower face area, as the face ages, facial tissues descend. This results in the so-called “laugh lines”. These and other folds and wrinkles are now commonly treated with subdermal and dermal injections of aesthetic facial fillers which add lost volume to the skin thereby reducing the appearance of the folds and wrinkles.
Hyaluronic acid (HA), also known as hyaluronan, is now one of the most commonly used components of dermal fillers. Hyaluronic acid is a naturally occurring, water soluble polysaccharide, specifically a glycosaminoglycan, which is a major component of the extra-cellular matrix and is widely distributed in animal tissues. The identical structure of hyaluronic acid in all species and tissues makes this polysaccharide an ideal substance for use as a bio-material in health and medicine.
HA has excellent biocompatibility and, unlike collagen, does not require any skin testing before implantation. In addition, HA has the ability to bind to large amounts of water, making it an excellent volumizer of soft tissues.
To enhance its longevity in vivo, the HA in dermal fillers is commonly crosslinked. Chemically crosslinked HA is formed by reacting uncrosslinked HA with a crosslinking agent under suitable reaction conditions.
It is generally accepted that HA-based dermal fillers having a high viscosity, for example, those that are highly crosslinked and/or made of high molecular weight HA and/or having a high HA concentration tend to last longer in the body. Conversely, it is generally accepted that HA-based dermal fillers having a low viscosity, for example, those that are more lightly crosslinked and/or made up of low molecular weight HA and/or have a low HA concentration, may have a shorter duration in the body. Naturally, injection of a high viscosity material through a needle is relatively more difficult, and generally requires a lower gauge needle (for instance, 21G or 23G compared to 27G or 30G) than injection of a relatively low viscosity material. It has proven difficult to develop an HA based composition that is both easy to inject through a high gauge needle (i.e. thin needle) and which has extended duration in the body.
The present invention relates to injectable compositions, and more specifically, to injectable compositions for intradermal injection into skin. The compositions and methods provide improved skin appearance and quality by filling of superficial skin depressions, and/or improving skin quality and appearance. In one aspect, the compositions and methods provide at least one of improved skin texture, increased skin hydration and increased elasticity.
In one aspect, the present compositions are based on hyaluronic acid (HA) and pharmaceutically acceptable salts of HA, for example, sodium hyaluronate (NaHA). Many of the long lasting, highly injectable compositions of the present invention include a crosslinked HA matrix made with relatively low molecular weight HA. In some embodiments, the compositions have a relatively low concentration of HA. Advantageously, many of the compositions provided herein have an extended duration of effect. For example, rather than requiring multiple repeated treatments every three to four weeks, as is common with conventional intradermal injection treatment methods, many of the present compositions and methods provided herein have a duration of effect of three months, four months, six months, to a year or more.
In a broad aspect of the invention, a composition is provided which generally comprises an HA gel containing, or consisting essentially of, a low molecular weight HA material. The HA component includes more than 50%, for example, at least 70%, for example, about 90% by weight of the low molecular weight HA. The low molecular weight HA material has a weight average molecular weight of no greater than about 0.20 MDa and about 0.99 MDa such as about 0.4 MDa to about 0.8 MDa.
In some embodiments, the HA gel may further contain a high molecular weight HA, that is, a HA material having a molecular weight of at least about 1.0 MDa to about 4.0 MDa. Generally, in embodiments of the invention including high molecular weight HA material, the weight average molecular weight of the high molecular weight HA material is at least twice that of the low molecular weight HA material.
The HA of the HA gel may be crosslinked. For example, the HA may be chemically crosslinked by a suitable crosslinking agent. In some embodiments, the crosslinking agent is selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), or 1,4-bis(2,3-epoxypropoxy)butane, or 1,4-bisglycidyloxybutane (all of which are commonly known as BDDE), 1,2-bis(2,3-epoxypropoxy)ethylene and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane.
In some embodiments, the composition has an HA concentration of about 10.0 mg/g up to about 17.0 mg/g. In some embodiments, the HA concentration is less than about 17.0 mg/g, for example, less than about 15.0 mg/g. In some embodiments, the HA concentration is between about 10.0 mg/g and about 14.0 mg/g. In some embodiments, the HA concentration is about 10.0 mg/g, about 11.0 mg/g, about 12.0 mg/g, about 13.0 mg/g, or about 14.0 mg/g.
In another aspect of the invention, methods of treating skin using the present compositions are provided. For example, methods of improving one or more qualities of skin, or improving appearance or texture of skin, are provided.
In one aspect, methods of treating dryness, texture or roughness, and/or elasticity in skin are provided. The methods generally comprise treating an area of skin by introducing, into the area, multiple, spaced apart injections of a composition comprising a hyaluronic acid (HA) gel containing crosslinked HA, wherein the treated skin maintains an improved hydration, smoother texture or increased elasticity, due to the treatment for an extended duration, for example, for at least about 3 months to about a year or more. In a particularly advantageous embodiment, the step of introducing is performed in only a single treatment session, thereby eliminating the need for repeated treatments to maintain the duration of effect.
In some embodiments, the step of introducing comprises introducing the composition in injections spaced apart by a distance of between about 2 mm to about 30 mm. For example, the step of introducing comprises introducing the composition in injections spaced apart by a distance of between about 5 mm to about 20 mm, or about 10 mm to about 15 mm. In some embodiments, the compositions are introduced at an injection depth of between about 500 microns and about 2000 microns, for example, a depth of about 1000 microns. In preferred embodiments, the compositions are introduced at an injection depth of between about 0.5 mm to about 5.0 mm, preferably about 1.0 mm to about 4.0 mm, more preferably from about 1.5 mm to about 3.0 mm. In general, a deeper injection provides improved hydration results.
In another aspect, the invention provides a method of treating roughness in skin comprising treating an area of skin by introducing, into the area, multiple, spaced apart injections of a composition comprising a hyaluronic acid (HA) gel containing crosslinked HA, wherein the treated skin maintains a smoother texture due to the treatment for at least about 3 months, at least about 4 months, at least about 6 months, or at least about 12 months.
The term “about” in the context of numerical values will be readily understood by a person skilled in the art, and preferably means that specific values may be modified by +/−10%. As regards endpoints of ranges, the modifier “about” preferably means that the lower endpoint may be reduced by 10% and the upper endpoint increased by 10%. It is also contemplated that each numerical value or range disclosed in this application can be absolute, i.e. that the modifier “about” can be deleted.
All numbers herein expressing “molecular weight” of HA are to be understood as indicating the weight average molecular weight (Mw) in Daltons.
The molecular weight of HA is calculated from an intrinsic viscosity measurement using the following Mark Houwink relation:
Intrinsic Viscosity (m3/kg)=9.78×10−5×Mw0.690
The intrinsic viscosity is measured according to the procedure defined European Pharmacopoeia (HA monograph N°1472, 01/2009).
High molecular weight HA as used herein describes a HA material having a molecular weight of at least about 1.0 million Daltons (Mw ≥106 Da or 1 MDa) to about 5.0 MDa. For example, the high molecular weight HA in the present compositions may have a molecular weight in the range about 1.5 MDa to about 3.0 MDa, or the high molecular weight HA may have a weight average molecular weight of about 2.0 MDa. In another example, the high molecular weight HA may have a molecular weight of about 3.0 MDa. In another example, the high molecular weight HA may have a molecular weight of about 1 MDa which corresponds to an intrinsic viscosity of 1.35 m3/kg when calculated according to the Mark Houwink relation as indicated above, 1.5 MDa (1.35 m3/kg), 2 MDa (2.18 m3/kg), 3 MDa (2.88 m3/kg), 5 MDa (4.10 m3/kg), 0.2 MDa (0.44 m3/kg), 0.4 MDa (0.72 m3/kg), 0.8 MDa (1.1 m3/kg), 0.99 MDa (1.34 m3/kg).
Low molecular weight HA as used herein describes a HA material having a molecular weight of less than about 1.0 MDa. Low molecular weight HA can have a molecular weight of between about 200,000 Da (0.2 MDa) to less than 1.0 MDa, for example, between about 400,000 Da and about 800,000 Da, for example about 386,000 Da (0.386 MDa) to about 740,000 Da (0.74 MDa). In some embodiments the low molecular weight HA used to make the crosslinked HA matrix does not exceed 0.99 MDa.
Preferably, the mixture of the low molecular weight HA and high molecular weight HA has a bimodal molecular weight distribution. The mixture may also have a multi-modal distribution.
In one aspect of the invention, the compositions comprise HA having a high molecular weight component and a low molecular weight component, and the high molecular weight component has a weight average molecular weight at least twice the weight average molecular weight of the low molecular weight component.
For example, a composition in accordance with this aspect of the invention may include a low molecular weight component having a weight average molecular weight of about 500,000 Da, and a high molecular weight component having a weight average molecular weight of about, or at least about, 1.0 MDa.
In another example, a composition in accordance with the invention may include a low molecular weight component having a weight average molecular weight of about 800,000 Da, and a high molecular weight component having a weight average molecular weight of about, or at least about, 1.6 MDa.
Degree of crosslinking is measured by the final weight ratio of crosslinker to HA disaccharide units.
Uncrosslinked HA as used herein refers to individual HA polymer molecules that are not crosslinked to one another. Uncrosslinked HA generally remains water soluble.
Provided herein are compositions for treating skin, for example, injectable compositions that can be introduced intradermally to improve the appearance or quality of skin, for example, to improve hydration, texture and/or elasticity. The compositions may also be effective for treatment of fine lines in skin and for reducing superficial cutaneous depressions. Methods of making these compositions are also provided, as well as methods of treatment using these compositions. The compositions are based on hyaluronic acids (HA) and pharmaceutically acceptable salts of HA, for example, sodium hyaluronate (NaHA).
As used herein, hyaluronic acid (HA) can refer to any of its hyaluronate salts, and includes, but is not limited to, sodium hyaluronate (NaHA), potassium hyaluronate, magnesium hyaluronate, calcium hyaluronate, and combinations thereof. Both HA and pharmaceutically acceptable salts thereof can be used in this invention.
Generally, the concentration of HA in some of the present compositions is about 10.0 mg/g up to about 17.0 mg/g. In some embodiments, the HA concentration is less than about 17.0 mg/g, for example, less than about 15.0 mg/g. In some embodiments, the HA concentration is between about 10.0 mg/g and about 14.0 mg/g. In some embodiments, the HA concentration is about 10.0 mg/g, about 11.0 mg/g, about 12.0 mg/g, about 13.0 mg/g, or about 14.0 mg/g.
Some of the compositions of the invention include additional agents, for example, anesthetic agents in an amount effective to mitigate pain experienced upon injection of the composition. The anesthetic agent may be selected from the group of ambucaine, amolanone, amylocaine, benoxinate, benzocaine, betoxycaine, biphenamine, bupivacaine, butacaine, butamben, butanilicaine, butethamine, butoxycaine, carticaine, chloroprocaine, cocaethylene, cocaine, cyclomethycaine, dibucaine, dimethisoquin, dimethocaine, diperodon, dicyclomine, ecgonidine, ecgonine, ethyl chloride, etidocaine, beta-eucaine, euprocin, fenalcomine, formocaine, hexylcaine, hydroxytetracaine, isobutyl p-aminobenzoate, leucinocaine mesylate, levoxadrol, lidocaine, mepivacaine, meprylcaine, metabutoxycaine, methyl chloride, myrtecaine, naepaine, octocaine, orthocaine, oxethazaine, parethoxycaine, phenacaine, phenol, piperocaine, piridocaine, polidocanol, pramoxine, prilocaine, procaine, propanocaine, proparacaine, propipocaine, propoxycaine, pseudococaine, pyrrocaine, ropivacaine, salicyl alcohol, tetracaine, tolycaine, trimecaine, zolamine, and salts thereof. In one embodiment, at least one anesthetic agent is lidocaine, such as in the form of lidocaine HCI. The compositions described herein may have a lidocaine concentration of between about 0.1% and about 5% by weight of the composition, for example, about 0.2% to about 1.0% by weight of the composition. In one embodiment, the composition has a lidocaine concentration of about 0.3% by weight (w/w %) of the composition.
In some embodiments, the compositions further comprise a beneficial additive, for example, an antioxidant. In some embodiments, the compositions include, for example, mannitol. The mannitol may be present in an amount of between about 0.1% w/w to about 2.0% w/w, or between about 0.3% to about 0.9% w/w. In some embodiments, the mannitol is present in an amount of less than, no greater than, or about 1.0% w/w. In some embodiments, the mannitol is present in an amount of about 0.9% w/w. In other embodiments, the mannitol is present in an amount of about 0.1% w/w, or about 0.2% w/w, or about 0.3% w/w, or about 0.4% w/w, or about 0.5% w/w, or about 0.6% w/w, or about 0.7% w/w, or about 0.8% w/w, or about 0.9% w/w, or about 1.0% w/w. In other embodiments, the mannitol is present in an amount of greater than about 1.0% w/w. In some embodiments, the mannitol is present in an amount of between about 1.0% w/w to about 5.0% w/w.
In some embodiments, the compositions further comprise a vitamin, for example, Vitamin C. In a more preferred embodiment, the vitamin is a derivative or a stabilized form of Vitamin C, for example, ascorbic acid 2-glucoside. The vitamin may be present in an amount of between about 0.1% to about 2.0% w/w, or between about 0.2% and about 1.0% w/w, or between about 0.3% to about 0.6% w/w. In some embodiments, the Vitamin C is present in an amount of about 0.6% w/w. In other embodiments, the Vitamin C derivative is present in an amount of about 0.1% w/w, or about 0.2% w/w, or about 0.3% w/w, or about 0.4% w/w, or about 0.5% w/w, or about 0.6% w/w, or about 0.7% w/w, or about 0.8% w/w, or about 0.9% w/w, or about 1.0% w/w. In other embodiments, the Vitamin C derivative is present in an amount of greater than 1.0%. In some embodiments, the Vitamin C derivative is present in an amount of between about 1.0% w/w to about 5.0% w/w.
In some embodiments, the compositions further comprise a combination of mannitol and ascorbic acid 2-glucoside. In some of these embodiments, the mannitol is present in an amount of no greater than 1.0% w/w, for example, 0.9% w/w and the ascorbic acid 2-glucoside is present in an amount of about 0.6% w/w.
In some embodiments, the compositions do not include an antioxidant or a vitamin. For example, in some embodiments, the compositions comprise or consist essentially of hyaluronic acid crosslinked with a crosslinking agent and water. These compositions may or may not include an anesthetic agent such as lidocaine.
The present products and compositions are preferably provided in a sterile form. The compositions may be sterilized using conventional methods, for example, autoclaving. For example, the compositions may be sterilized by exposing the compositions to temperatures of at least about 120° C. to about 130° C. and/or pressures of at least about 12 pounds per square inch (PSI) to about 20 PSI for a period of at least about 1 minute to about 15 minutes.
Method of making the composition comprise the steps of providing raw HA material in the form of dry HA fibers or powder. The raw HA material may be HA, its salts and/or mixtures thereof. In a preferred embodiment, the HA material comprises fibers or powder of NaHA, for example, bacterial-sourced NaHA fibers. In some aspects of the present description, the HA material may be animal derived. The HA material may be a combination of raw materials including HA and at least one other polysaccharide, for example, glycosaminoglycan (GAG).
In a broad aspect of the invention, the HA material of the compositions may comprise a crosslinked HA matrix made with between about 5% to about 95% low molecular weight HA with the balance of the HA material including high molecular weight HA.
In some embodiments of the invention, the HA material used to make the present compositions nearly entirely comprises or consists of low molecular weight HA. In some embodiments, nearly 100% of the HA material used to make the present compositions may be low molecular weight HA as defined above. In other embodiments, the HA material used to make the compositions comprises a combination of relatively high molecular weight HA and relatively low molecular weight HA, as defined above. In certain embodiments, at least about 50% w/w, for example, at least about 70% w/w, for example, at least about 90% w/w or greater of the HA material in the compositions is a low molecular weight HA as defined above, with the remaining portion of HA being high molecular weight HA. In one embodiment, the compositions are made using a 90:10 ratio of low molecular weight HA to high molecular weight HA. That is, the compositions of these embodiments are made with a combination of high and low molecular weight HA, with about 90% w/w of the HA being the low molecular weight HA.
In one embodiment, the pure, dry NaHA fibers are hydrated in an alkaline solution to produce an uncrosslinked NaHA gel. Any suitable alkaline solution may be used to hydrate the NaHA in this step, for example, but not limited to aqueous solutions containing sodium hydroxide (NaOH), potassium hydroxide (KOH), sodium bicarbonate (NaHCO3), lithium hydroxide (LiOH), and the like. In another embodiment, the suitable alkaline solution is aqueous solutions containing NaOH. The resulting alkaline gel will have a pH above 7.5. The pH of the resulting alkaline gel can have a pH greater than 9, or a pH greater than 10, or a pH greater than 11, or a pH greater than 12, ora pH greater than 13.
The next step in the manufacturing process involves the step of crosslinking the hydrated, alkaline NaHA gel with a suitable crosslinking agent. The crosslinking agent may be any agent known to be suitable for crosslinking polysaccharides and their derivatives via their hydroxyl groups. Suitable crosslinking agents include but are not limited to, 1,4-butanediol diglycidyl ether (or 1,4-bis(2,3-epoxypropoxy)butane or 1,4-bisglycidyloxybutane, all of which are commonly known as BDDE), 1,2-bis(2,3-epoxypropoxy)ethylene and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane. The use of more than one crosslinking agent or a different crosslinking agent is not excluded from the scope of the present disclosure. In one embodiment, the HA gels described herein are crosslinked using BDDE.
The step of crosslinking may be carried out using any means known to those of ordinary skill in the art. Those skilled in the art appreciate how to optimize conditions of crosslinking according to the nature of the HA, and how to carry out crosslinking to an optimized degree.
In another embodiment, the crosslinking of the HA is accomplished during hydration of the HA fibers, by hydrating the combined high and low molecular weight fibers in an alkaline solution containing a crosslinking agent, for example, BDDE.
The degree of crosslinking in the HA component of the present compositions is at least about 1% and is up to about 20% BDDE/HA, w/w, for example, between about 4% and about 12% w/w, for example, about 10% w/w, for example, about 8% w/w, for example, about 6% w/w, for example, about 5% w/w, for example, about 4% w/w.
The hydrated crosslinked, HA gels may be swollen to obtain the desired HA concentration. This step can be accomplished by neutralizing the crosslinked, hydrated HA gel, for example by adding an aqueous solution containing of an acid, such as HCI. The gels are then swelled in a phosphate buffered saline (PBS) solution.
The gels may be purified by conventional means such as, dialysis against a phosphate buffer, or alcohol precipitation, to recover the crosslinked material, to stabilize the pH of the material and to remove any un-reacted crosslinking agent. The compositions are mixed to achieve homogeneity. Preferably, the homogenization step comprises mixing, stirring, or beating the gels with a controlled shearing force obtaining substantially homogenous mixtures. In some embodiments, during or after the mixing, a phosphate buffer is added to reach the desired concentration of HA in the final composition.
In some embodiments, lidocaine (e.g. in the form of lidocaine HCI), or another suitable anesthetic, is added to the compositions. For example, the pH of the purified, substantially pH neutral, gel is adjusted to cause the gel to become slightly alkaline such that the gels have a pH of greater than about 7.2, for example, about 7.5 to about 8.0. Alternatively, the gel is adjusted to cause the gel to become alkaline such that the gels have a pH of greater than about 9, for example, about 10.0 to about 11.0. This step may be accomplished by any suitable means, for example, by adding to the gels a suitable amount of dilute NaOH, KOH, NaHCO3 or LiOH, or any other alkaline molecule, solution and/or buffering composition know by one skilled in the art. For example, in some embodiments, the lidocaine HCI is provided in a powder form which is solubilized using water for injection (WFI). The lidocaine is then added to the (slightly) alkaline gel. Uncrosslinked HA may then be added to the lidocaine-containing gel, if desired. For example, in one embodiment, the desired HA concentration is about 12.0 mg/g. The compositions including lidocaine may have a lidocaine concentration of between about 0.1% and about 5% by weight of the composition, for example, about 0.3% by weight (or w/w), based on the total weight of the composition. The compositions including uncrosslinked HA may have an uncrosslinked HA concentration of less than 10% w/w or less than 5% w/w such as preferably between about 0.5% and about 1.5% by weight of the composition, for example, about 0.9 to 1.0%, based on the total weight of the composition. The uncrosslinked HA has preferably a high molecular weight.
The compositions are introduced into delivery devices, for example, syringes. Syringes useful according to the present description include any syringe known in the art capable of delivering viscous dermal filler compositions. The syringes may have an internal volume of about 0.4 mL to about 3 mL, between about 0.5 mL and about 1.5 mL or between about 0.8 mL and about 1.0 mL.
In other embodiments, the compositions are introduced into injection devices suitable for delivering the compositions using multiple microdepot injections, into relatively shallow, superficial, surfaces of skin.
The gauges of needles used to deliver the present compositions include gauges of between about 18G and about 40G. In some embodiments, the needles for delivering the compositions are between about 25G to about 33G such as between about 31G to about 33G or about 32G to about 33G. In some embodiments, the compositions are delivered using a needle having a gauge of 28G, 29G, 30G, 32G or 33G.
In another aspect of the invention, methods of treating skin using the present compositions are provided. For example, methods of improving one or more qualities of skin, or improving appearance or texture of skin, are provided.
In one aspect, methods of treating dryness, texture or roughness, and/or elasticity in skin are provided. The methods generally comprise treating an area of skin by introducing, into the area, multiple, spaced apart injections of a composition comprising a hyaluronic acid (HA) gel containing crosslinked HA, wherein the treated skin maintains an improved hydration, smoother texture or increased elasticity, due to the treatment for an extended duration, for example, for at least about 3 months to about a year or more.
In a particularly advantageous embodiment, the step of introducing is performed in only a single treatment session, thereby eliminating the need for repeated treatments to maintain the duration of effect.
In one aspect of the invention, a method of treating skin in provided comprising introducing the composition into the skin during a treatment session comprising multiple injections of the composition into a skin region.
In one embodiment, a treatment session comprises a single visit by the patient to a practitioner. During the treatment session, multiple injections into the skin, for example into a particular skin region, may be administered.
The multiple injections of a single treatment session may comprise, for example, from 2 to about 500 injections, from about 50 to about 200 injections. In some embodiments, a treatment session comprises, for example, at least 2 injections, at least 10 injections, at least 20 injections, at least 40 injections, at least 60 injections, at least 80 injections, at least 100 injections, at least 140 injections, at least 180 injections, at least 200 injections, at least 300 injections, at least 400 injections at least 500 injections, or more, into the skin region.
In some embodiments, the treatment session takes no longer than about 45 minutes, no longer than about 30 minutes, no longer than about 15 minutes, or no longer than about 10 minutes per treatment area. Treatment area is defined as a skin region being treated with the present compositions and methods. The treatment area may comprise or consist of a skin region of at least one of a face, a neck, or a décolletage. The treatment area may also comprise or consist of a region of skin other than a face, neck or décolletage, for example, a skin region of the top of the hand, a knee, an elbow, a forearm, a calf, a thigh, a back, or any other region of skin that can be treated using the present compositions and methods and can be benefitted or improved thereby.
In some embodiments, the step of introducing comprises introducing the composition in injections spaced apart by a distance of between about 2 mm to about 30 mm. For example, the step of introducing comprises introducing the composition in injections spaced apart by a distance of between about 5 mm to about 20 mm. In some embodiments, the step of introducing comprises introducing the composition in injections spaced apart by a distance of between about 10 mm to about 15 mm.
In some embodiments, the injections are provided at a very superficial depth in the skin. For example, in some embodiments, the compositions are introduced at a depth of no greater than about 2000 microns. For example, the injections may be provided at a depth of about 500 microns to about 2000 microns, about 800 microns to about 1600 microns, about 1000 microns to about 1200 microns. In preferred embodiments, the compositions are introduced at an injection depth of between about 0.5 mm to about 5.0 mm, preferably about 1.0 mm to about 4.0 mm, more preferably from about 1.5 mm to about 3.0 mm. In one embodiment, the injections are introduced in an amount of about 1 pL to about 200 pL, for example, about 5 pL to about 100 pL per injection, for example, between about 20 pL to about 80 pL, for example, about 40 pL to about 60 pL per injection. In some embodiments, the injections are introduced in an amount of about 5 pL to about 500 pL per injection, about 10 pL to about 400 pL, about 50 pL to about 200 pL, or about 100 pL per injection.
In some embodiments, the injections are delivered through a needle having a gauge of at least 27 G, for example, 28 G, 30 G or 32 G.
Advantageously, method of treatment may comprise or consist of a single treatment session lasting a relatively short amount of time. In some embodiments, the treatment session covering the region of skin being treated, comprises multiple, intradermal injections into the skin region, and takes no longer than about 45 minutes. In some embodiments, the treatment session takes no longer than about 30 minutes. In yet other embodiments, the treatment session takes no longer than about 20 minutes, or no longer than about 15 minutes, or no longer than about 10 minutes.
A method of treating roughness in skin is also provided, wherein the method comprises treating an area of skin by introducing, into the area, multiple, spaced apart injections of a composition comprising a hyaluronic acid (HA) gel containing crosslinked HA wherein the treated skin maintains a smoother texture due to the treatment for at least about 3 months, for at least about 4 months, for at least about 6 months, for at least about 9 months, or for at least about 12 months.
In a particular embodiment, the compositions of the invention comprise a sterile physiological solution of hyaluronic acid (HA) gel of non-animal origin cross-linked with 1,4-Butanediol Diglycidyl ether (BDDE) at a concentration of 12 mg/mL. The compositions are useful for treatment of superficial skin depressions as measured by improvement in skin texture and improvement of skin quality, such as smoothness, hydration and elasticity, as compared to non-treated superficial skin depressions. In a particular embodiment, methods of treatment include injections, for example, depot injections, into the dermis using a 32G needle across the target anatomic region(s). The target anatomic regions include skin regions of the face, and skin regions of the neck. The improvement of skin appearance, for example, reduced appearance of depressions, fine lines and uneven or rough texture as compared to untreated skin, may be markedly noticeable by the patient, and the improvement may last for a duration of at least 4 months, 6 months, 9 months or even 12 months, after a single treatment session lasting only 45 minutes, or only 30 minutes, or only 20 minutes, or only 15 minutes, or less. Improvement of skin texture can be evaluated using appropriate scales. Skin quality measurements of hydration and elasticity can be performed, using appropriate instrumentation, and compared to baseline, i.e. untreated skin. Other evaluation methods, for example, FACE Q and GAIS can be utilized to assess subject and investigator satisfaction, respectively. In a specific embodiment, the duration of action of the product after the treatment is at least about 4 months for example, about 6 months.
The addition of lidocaine to the compositions, in some embodiments, reduces pain in the treatment area. However, in some embodiments, the compositions do not include lidocaine, in order to address patient need with regard to allergy to lidocaine and pain sensitivity.
Another embodiment provides a method of increasing at least one of smoothness, hydration, and elasticity in skin comprising introducing, into a skin region at a depth of between about 500 microns and about 5000 microns, in a single treatment session, multiple, spaced apart injections of a composition comprising a hyaluronic acid (HA) gel containing BDDE-crosslinked HA and uncrosslinked HA, wherein the injections are introduced in an amount of about 5 pL to about 100 pL per injection, wherein the injections are delivered through a needle having a gauge of from 28 G to 33 G, wherein the injections are spaced apart by a distance of between about 5 mm to about 20 mm.
In some embodiments, the skin region maintains an increased smoothness, hydration, and/or elasticity due to the treatment for at least about 3 months, about 4 months, about 5 months, about 6 months, 9 months, 12 months, or longer.
In another embodiment, a composition for increasing at least one of smoothness, hydration, and elasticity in skin is provided comprising a hyaluronic acid (HA) gel comprising a crosslinked HA matrix made with a low molecular weight HA material having a weight average molecular weight of between about 400,000 Da and about 800,000 Da; wherein the HA concentration of the composition is from about 10.0 mg/g to about 14.0 mg/g; and wherein the composition maintains the increased smoothness, hydration, and/or elasticity due to the treatment for at least about 6 months from being introduced into the skin in a single treatment session comprising multiple, spaced apart injections of the composition in which the injections are introduced in an amount of about 5 pL to about 100 pL per injection, delivered through a needle having a gauge of from 28 G to 33 G and are spaced apart by a distance of between about 5 mm to about 20 mm. The skin region may maintain an increased smoothness, hydration, and/or elasticity due to the treatment for at least about 3 months, about 4 months, about 5 months, about 6 months, 9 months, 12 months, or longer. The compositions may further include at least one of a mannitol and a Vitamin C. In some embodiments, both mannitol and a Vitamin C derivative are present in the compositions.
The compositions are associated with a gel hardness G′ of between about 50 to 200 Pa, such as 100-150 Pa or 120 Pa, when measured at 0.1 Hz or between about 100 to 300 Pa, such as 150 to 200 Pa or 175 Pa, when measured at 5 Hz. The method for measuring the gel hardness is known in the art. The gel hardness is indicative for the dermal filler's softness.
The compositions are further associated with a gel viscosity G″ of between about 10 to 100 Pa, such as 15-40 Pa or 20 Pa, when measured at 0.1 Hz or between about 10 to 100 Pa, such as 20-40 Pa or 30 Pa, when measured at 5 Hz. The method for measuring the visosity is known in the art.
The compositions are also associated with a compression of between about 5 to 20 N, such as 10-15 N or 12 N. The method for measuring the compression is known in the art. The compression is indicative for the dermal filler's resistance to deformation. Generally, the lower the compression, the lower the filler's lift spreadibility, i.e. the filler is then more suitable for treating superficial lines and folds in the face or neck as compared to fillers having a higher compression which are more suitable for deeper injections and volume restorations.
The free radical degradation test allows to evaluate the resistance of a gel sample toward the degradation of the HA chains by the free radicals (one of the main degradation pathway of HA). Free radical degradation tests was carried out on 3 different batches of the present compositions. The results obtained are presented on the Table1. All measures were found to conform (CVr<10%).
The inter-batch variability is around 3% on the 3 different batches and the average value of degradation time is 4985 s (Table 2).
A 37-year old woman presents with rough, dry facial skin due to aging, dry climate and/or sun/wind exposure over the course of her lifetime. The physician administers, by intradermal, micro-depot injections, the compositions described herein. The treatment consists of from 10 to about 100 shallow injections per skin region, with a 32 G/4 mm needle. The skin regions treated are the face, neck, and décolleté. The treatment session, over the total of all of the skin regions of the patient, lasts about 40 minutes from the initial injection to the final injection. Each treatment region receives an appropriate amount of the composition in spaced apart injections. The facial region for example, receives about 2 mL to about 3 mL of the composition, administered by shallow single injections spaced apart approximately every 10 mm to about 15 mm. The neck is treated with about 1 mL to 2 mL of the composition, the injections spaced apart approximately every 15 mm to about 20 mm. After the treatment, the areas of the skin treated are examined by the senses of sight, touch and pressure. A photographic evaluation is performed at the beginning and at the end of the treatment. The patient reports to the physician that the treatment has caused only minimum discomfort. The patient returns to her everyday activities immediately after the treatment. In a small area on the skin of her treated right hand, ecchymosis is found, but this resolves a few days after the application of an anti-inflammatory cream. The patient returns to the physician 4 months after the treatment for a follow up evaluation. Prior to the follow up evaluation visit, no further injections of fillers or mesotherapy treatments are performed on the patient. On objective examination at the follow up visit, the treatment has resulted in an improvement in the epidermal texture, and decreased dryness, and improved brightness of the skin. These improvements are evidenced in part by the photographic documentation. The treated skin regions are gently palpated and seem to have an increase in hydration, suppleness, elasticity and tone. The patient expresses a high degree of satisfaction with the treatment via the completion of a self-assessment questionnaire. The patient claims the treated areas have improved and she is very happy with the results. Interestingly, these good results are achieved based on only the single treatment session, with no repeated injections, “top-ups”, or further injection treatment between the time of the treatment session and the follow up visit.
The hydration of the injectable compositions on the epidermal and dermal structures of human living skin explants has been evaluated by corneometry measurements: Using a CM825 Comeometer® (COURAGE & KHAZAKA) the humidity level of the most external cutaneous layers of the stratum corneum have been determined. The action principle of the Corneometer® is based on the modification of the electrical capacities of the detector which is designed in the form of a condenser. The surface of the measurement head, in contact with the skin, modifies its electrical capacity according to the humidity level of the skin. On DO (=day 0), the electric epidermal capacitance expressed in AU (arbitrary unit) is an index of the skin hydration. The following composition according to the present disclosure has been determined:
The product has been stored at room temperature within the duration of the study.
Explant preparation: On an abdominal plasty coming from a 45-year-old Caucasian woman, 9 explants were prepared. The explants were kept in survival in BEM medium (BIO-EC's Explants Medium) at 37° C. in a humid, 5%-CO2 atmosphere. The explants were distributed in 3 batches (Nb=Number):
Product application: The explants of the batch Cl used for corneometry were treated with 4×10 pl of the injectable product (square injection) with each point of injection separated by 0.5 cm (see
Corneometry: An index of skin hydration, epidermal capacitance, was assessed using the CM825 Corneometer® (COURAGE & KHAZAKA) on the explants at D0, D2, D7 and D9. The measures have been performed at the centre of the square explants using a probe of 1 cm of diameter. Ten measurements are performed and the average value is calculated by the corneometer.
Sampling: On D0, three explants from the batch T0 were collected and cut in 2 parts: half was frozen at −80° C. and half was fixed in formol. On D2, D7 and D9, 3 explants from each batch were collected and processed in the same way.
Statistical analysis: The statistical analysis is performed according the Student t-test. Student t test gives the probability “p” for two batches to be significantly different. The difference between two batches is significant if p<0.05(*), so a probability of 95% for two batches to be significantly different; or if p<0.01(**), so a probability of 99% for two batches to be significantly different.
RESULTS: Measurement of corneometry for each batch (see also
The corneometry shows that with the product Pc1, the corneometry values are higher by 44.0%** vs T on D2, 34.9%** vs T on D7, and 43.6%** vs T on D9. With the product Pc2, the corneometry values are higher by 30.7%* vs T on D2, 38.6%** vs T on D7, and 41.9%** vs T on D9. (According to Student t-test: * significant with p<0.05 (95%); ** significant with p<0.01 (99%)). The compositions according to the present disclosure show a good hydration activity whatever the condition tested (4 injections of 10 pl each separated by 0.5 cm or 1 cm for Pc1 and Pc2 respectively), it induces a strong increment of epidermal capacitance values which increases the skin hydration.
The skin hydration of the injectable compositions according to the present disclosure on the epidermal and dermal structures of human living skin explants has been evaluated by additional corneometry measurements. The following compositions have been determined:
The products have been stored at room temperature within the duration of the study.
Explant preparation: For the first donor, 9 explants of 1.5 cm×2 cm in size were prepared on an abdominal plasty coming from a 59-year-old Caucasian woman. For the second donor, 9 explants of 1.5 cm×2 cm in size were prepared on an abdominal plasty coming from a 42-year-old Caucasian woman. For the third donor, 9 explants of 1.5 cm×2 cm in size were prepared on an abdominal plasty coming from a 52-year-old Caucasian woman. For each donor, 9 explants were distributed in 3 batches as follows:
Product application: On D0, 3×50pL of the products P1 or P2 were injected with a needle into the dermis of the rectangular explants (1.5×2 cm). The untreated controls did not receive any treatment.
Half of the culture medium (1 ml) was refreshed on D1, D2, D5 and D7.
Corneometry: An index of skin hydration, epidermal capacitance, was assessed using the CM825 Corneometer® (COURAGE & KHAZAKA) on the explants at D0, D1, D2 and D8.
RESULTS: The results of the corneometry measurements for the three donors and expressed as an average of three values (see also
For the 3 donors, the corneometry shows that the product P1 induces an increase of 15% on D1 of corneometry value compared to D0, continues to increase to 18% on D2 and increases to 22% on D8. The product P2 induces a quick increase of 37% increase from D0 to D1 and continues to increase from D2 to D8 to reach 49%. According to these experimental conditions and compared to the blank batch on D8 (TJ8), the following may be concluded:
Overall, under the experimental conditions of this study, the results show that the product according to the present disclosure (P2) shows an increased skin hydration in the stratum corneum on day 8 (D8) as compared to the product P1 and the untreated control T.
Although the invention has been described and illustrated with a certain degree of particularity, it is understood that the present disclosure has been made only by way of example, and that numerous changes in the combination and arrangement of parts, steps and elements can be resorted to by those skilled in the art without departing from the scope of the invention, as hereinafter claimed.
Illustration of Subiect Technology as Clauses
Various examples of aspects of the disclosure are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples, and do not limit the subject technology. Identifications of the figures and reference numbers are provided below merely as examples and for illustrative purposes, and the clauses are not limited by those identifications.
Clause 1. An injectable composition useful for reducing the appearance of superficial depressions in the skin, the composition comprising: a hyaluronic acid (HA) gel comprising a crosslinked HA matrix made with a low molecular weight HA material having a weight average molecular weight of between 0.20 about MDa and about 0.99 MDa; wherein the HA concentration of the composition is less than about 17.0 mg/g; wherein the composition maintains the reduced appearance of superficial depressions in the skin for at least about 3 months from being introduced into the skin.
Clause 2. The composition of Clause 1 wherein the composition maintains the reduced appearance of superficial depressions in the skin for at least about 6 months from being introduced into the skin.
Clause 3. The composition of Clause 1 wherein the composition maintains the reduced appearance of superficial depressions in the skin for at least about 9 months from being introduced into the skin.
Clause 4. The composition of Clause 1 further comprising at least one of mannitol and a vitamin C derivative.
Clause 5. The composition of Clause 4 wherein the mannitol is present in an amount of between about 0.3% to about 0.9% w/w.
Clause 6. The composition of Clause 4 wherein the vitamin C derivative is ascorbic acid 2-glucoside.
Clause 7. The composition of Clause 6 wherein the ascorbic acid 2-glucoside is present in an amount of between about 0.3% to about 0.6% w/w.
Clause 8. The composition of Clause 1 further comprising about 0.9% w/w mannitol and about 0.6% w/w ascorbic acid 2-glucoside.
Clause 9. The composition of Clause 1 wherein the weight average molecular weight of the low molecular weight HA material is between about 400,000 Da and about 800,000 Da.
Clause 10. The composition of Clause 1 wherein the crosslinked HA matrix is crosslinked with a crosslinking agent selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), 1,4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene and 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane.
Clause 11. The composition of Clause 1 wherein the HA concentration is about 10.0 mg/g to about 14.0 mg/g.
Clause 12. The composition of Clause 1 wherein the HA concentration is about 12.0 mg/g.
Clause 13. An injectable composition useful for reducing the appearance of superficial depressions in the skin or for improving skin quality, the composition comprising: a hyaluronic acid (HA) gel comprising a crosslinked HA matrix; at least one of a mannitol and a Vitamin C derivative; wherein the HA concentration of the composition is less than about 17.0 mg/g; wherein the composition maintains the reduced appearance of superficial depressions in the skin or the improved skin quality for at least about 3 months from being introduced into the skin.
Clause 14. The composition of Clause 13 wherein the composition maintains the reduced appearance of superficial depressions in the skin or the improved skin quality for at least about 6 months from being introduced into the skin.
Clause 15. The composition of Clause 13 wherein the composition maintains the reduced appearance of superficial depressions in the skin or the improved skin quality for at least about 9 months from being introduced into the skin.
Clause 16. The composition of Clause 13 wherein the mannitol is present in an amount of between about 0.3% to about 0.9% w/w.
Clause 17. The composition of Clause 13 wherein the vitamin C derivative is ascorbic acid 2-glucoside.
Clause 18. The composition of Clause 17 wherein the ascorbic acid 2-glucoside is present in an amount of between about 0.3% to about 0.6% w/w.
Clause 19. The composition of Clause 13 wherein the at least one of a mannitol and a Vitamin C derivative comprises both mannitol present at about 0.9% w/w and a Vitamin C derivative present at about 0.6% w/w.
Clause 20. The composition of Clause 19 wherein the Vitamin C derivative is ascorbic acid 2-glucoside.
Clause 21. The composition of Clause 13 wherein the HA concentration is about 10.0 mg/g to about 14.0 mg/g.
Clause 22. The composition of Clause 13 wherein the HA concentration is about 12.0 mg/g.
Clause 23. A method of improving at least one of texture, hydration and elasticity of skin, the method comprising; treating an area of skin by introducing into a skin region, in a single treatment session, multiple, spaced apart injections of a composition comprising a hyaluronic acid (HA) gel containing crosslinked HA; wherein the HA concentration of the composition is less than about 17.0 mg/g; wherein the treated skin maintains at least one of an improved texture, hydration and elasticity due to the treatment for at least about 3 months.
Clause 24. The method of Clause 23 wherein the treated skin maintains the at least one of an improved texture, hydration and elasticity due to the treatment for at least about 6 months.
Clause 25. The method of Clause 23 wherein the treated skin maintains the at least one of an improved texture, hydration and elasticity due to the treatment for at least about 12 months.
Clause 26. The method of Clause 23 wherein the HA concentration is about 10.0 mg/g to about 14.0 mg/g.
Clause 27. The method of Clause 23 wherein the HA concentration is about 12.0 mg/g.
Clause 28. The method of Clause 23 wherein the injections are spaced apart by a distance of between about 5 mm to about 20 mm.
Clause 29. The method of Clause 23 wherein the injections are introduced in an amount of about 5 pL to about 100 pL per injection.
Clause 30. The method of Clause 23 wherein the treatment takes no longer than about 45 minutes.
Clause 31. The method of Clause 23 wherein the injections are delivered through a needle having a gauge of from 28 G to 33 G.
Clause 32. The method of Clause 23 wherein the composition further comprising at least one of mannitol and a vitamin C derivative.
Clause 33. The method of Clause 23 wherein the mannitol is present in an amount of between about 0.3% and about 0.9% w/w.
Clause 34. The method of Clause 23 wherein the vitamin C derivative is ascorbic acid 2-glucoside.
Clause 35. The method of Clause 34 wherein the ascorbic acid 2-glucoside is present in an amount of between about 0.3% and about 0.6% % w/w.
Clause 36. A method of increasing at least one of smoothness, hydration, and elasticity in skin comprising; introducing, into a skin region at a depth of between about 0.5 to about 4.0 mm or about 0.5 to about 5.0 mm, in a single treatment session, multiple, spaced apart injections of a composition comprising a hyaluronic acid (HA) gel containing BDDE-crosslinked HA and uncrosslinked HA; wherein the injections are introduced in an amount of about 5 pL to about 100 pL per injection; wherein the injections are delivered through a needle having a gauge of from 28 G to 33 G; wherein the injections spaced apart by a distance of between about 5 mm to about 20 mm; and wherein the skin region maintains an increased smoothness, hydration, and/or elasticity due to the treatment for at least about 6 months.
Clause 37. The method of Clause 36 wherein the composition further comprises at least one of mannitol and a vitamin C derivative.
Clause 38. A composition for increasing at least one of smoothness, hydration, and elasticity in skin comprising: a hyaluronic acid (HA) gel comprising a crosslinked HA matrix made with a low molecular weight HA material having a weight average molecular weight of between about 400,000 Da and about 800,000 Da; wherein the HA concentration of the composition is from about 10.0 mg/g to about 14.0 mg/g; and wherein the composition maintains the increased smoothness, hydration, and/or elasticity due to the treatment for at least about 6 months from being introduced into the skin in a single treatment session comprising multiple, spaced apart injections of the composition in which the injections are introduced in an amount of about 5 pL to about 100 pL per injection, delivered through a needle having a gauge of from 28 G to 33 G and are spaced apart by a distance of between about 5 mm to about 20 mm.
Clause 39. The composition of Clause 38 wherein the composition further comprises at least one of mannitol and a vitamin C derivative.
| Number | Date | Country | Kind |
|---|---|---|---|
| PCT/IB2015/000347 | Feb 2015 | WO | international |
This application is a divisional of U.S. Ser. No. 15/549,990, filed on Aug. 9, 2017, which is a U.S. National Phase Application under 37 C.F.R. § 371 based upon International Application No. PCT/EP2016/052682, filed Feb. 9, 2016, which claims the benefit of and priority to International Application No. PCT/162015/000347, filed Feb. 9, 2015, the entireties of each of which is incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2128827 | Killian | Aug 1938 | A |
| 3548056 | Eigen et al. | Dec 1970 | A |
| 3763009 | Suzuki et al. | Oct 1973 | A |
| 3949073 | Daniels et al. | Apr 1976 | A |
| 4060081 | Yannas et al. | Nov 1977 | A |
| 4140537 | Luck et al. | Feb 1979 | A |
| 4233360 | Luck et al. | Nov 1980 | A |
| 4273705 | Kato | Jun 1981 | A |
| 4279812 | Cioca | Jul 1981 | A |
| 4424208 | Wallace et al. | Jan 1984 | A |
| 4501306 | Chu et al. | Feb 1985 | A |
| 4582640 | Smestad et al. | Apr 1986 | A |
| 4582865 | Balazs et al. | Apr 1986 | A |
| 4605691 | Balazs et al. | Aug 1986 | A |
| 4636524 | Balazs et al. | Jan 1987 | A |
| 4642117 | Nguyen et al. | Feb 1987 | A |
| 4713448 | Balazs et al. | Dec 1987 | A |
| 4716154 | Malson et al. | Dec 1987 | A |
| 4772419 | Malson et al. | Sep 1988 | A |
| 4803075 | Wallace et al. | Feb 1989 | A |
| 4886787 | De Belder et al. | Dec 1989 | A |
| 4896787 | Delamour et al. | Jan 1990 | A |
| 5009013 | Wiklund | Apr 1991 | A |
| 5087446 | Suzuki et al. | Feb 1992 | A |
| 5091171 | Yu et al. | Feb 1992 | A |
| 5143724 | Leshchiner | Sep 1992 | A |
| 5246698 | Leshchiner et al. | Sep 1993 | A |
| 5314874 | Miyata et al. | May 1994 | A |
| 5328955 | Rhee et al. | Jul 1994 | A |
| 5356883 | Kuo et al. | Oct 1994 | A |
| 5399351 | Leshchiner et al. | Mar 1995 | A |
| 5428024 | Chu et al. | Jun 1995 | A |
| 5492936 | Francese et al. | Feb 1996 | A |
| 5531716 | Luzio et al. | Jul 1996 | A |
| 5565519 | Rhee et al. | Oct 1996 | A |
| 5571503 | Mausner | Nov 1996 | A |
| 5614587 | Rhee et al. | Mar 1997 | A |
| 5616568 | Pouyani et al. | Apr 1997 | A |
| 5616611 | Yamamoto et al. | Apr 1997 | A |
| 5616689 | Shenoy et al. | Apr 1997 | A |
| 5633001 | Agerup | May 1997 | A |
| 5643464 | Rhee et al. | Jul 1997 | A |
| 5676964 | Della Valle et al. | Oct 1997 | A |
| 5823671 | Mitchell et al. | Oct 1998 | A |
| 5824333 | Scopelianos et al. | Oct 1998 | A |
| 5827529 | Ono et al. | Oct 1998 | A |
| 5827937 | Agerup | Oct 1998 | A |
| 5843907 | Sakai et al. | Dec 1998 | A |
| 5880107 | Buenter | Mar 1999 | A |
| 5886042 | Yu et al. | Mar 1999 | A |
| 5935164 | Iverson | Aug 1999 | A |
| 5980930 | Fenton et al. | Nov 1999 | A |
| 6013679 | Kuo et al. | Jan 2000 | A |
| 6066325 | Wallace et al. | May 2000 | A |
| 6224857 | Romeo et al. | May 2001 | B1 |
| 6335035 | Drizen et al. | Jan 2002 | B1 |
| 6372494 | Naughton et al. | Apr 2002 | B1 |
| 6383218 | Sourdille et al. | May 2002 | B1 |
| 6383219 | Telandro et al. | May 2002 | B1 |
| 6418934 | Chin | Jul 2002 | B1 |
| 6521223 | Calias et al. | Feb 2003 | B1 |
| 6544503 | Vanderhoff et al. | Apr 2003 | B1 |
| 6586493 | Massia et al. | Jul 2003 | B1 |
| 6627620 | Niclscn | Sep 2003 | B1 |
| 6630486 | Royer | Oct 2003 | B1 |
| 6685963 | Taupin et al. | Feb 2004 | B1 |
| 6716251 | Asius et al. | Apr 2004 | B1 |
| 6734298 | Barbucci et al. | May 2004 | B1 |
| 6767924 | Yu et al. | Jul 2004 | B2 |
| 6767928 | Murphy et al. | Jul 2004 | B1 |
| 6852255 | Yang et al. | Feb 2005 | B2 |
| 6893466 | Tricu | May 2005 | B2 |
| 6903199 | Moon et al. | Jun 2005 | B2 |
| 6921819 | Piron et al. | Jul 2005 | B2 |
| 6924273 | Pierce | Aug 2005 | B2 |
| 6939562 | Spiro et al. | Sep 2005 | B2 |
| 6979440 | Shefer et al. | Dec 2005 | B2 |
| 7119062 | Alvis et al. | Oct 2006 | B1 |
| 7166570 | Hunter et al. | Jan 2007 | B2 |
| 7192984 | Berg et al. | Mar 2007 | B2 |
| 7196180 | Aeschlimann et al. | Mar 2007 | B2 |
| 7314636 | Caseres et al. | Jan 2008 | B2 |
| 7491709 | Carey | Feb 2009 | B2 |
| 7741476 | Lebreton | Jun 2010 | B2 |
| 7902171 | Reinmuller et al. | Mar 2011 | B2 |
| 8124120 | Sadozai et al. | Feb 2012 | B2 |
| 9898263 | Zhang | Feb 2018 | B2 |
| 20020102311 | Gustavsson et al. | Aug 2002 | A1 |
| 20020160109 | Yeo et al. | Oct 2002 | A1 |
| 20030031638 | Joshi et al. | Feb 2003 | A1 |
| 20030093157 | Casares et al. | May 2003 | A1 |
| 20030119985 | Sehl et al. | Jun 2003 | A1 |
| 20030148995 | Piron et al. | Aug 2003 | A1 |
| 20040032056 | Vang et al. | Feb 2004 | A1 |
| 20040101959 | Marko et al. | May 2004 | A1 |
| 20040127698 | Tsai et al. | Jul 2004 | A1 |
| 20040127699 | Zhao et al. | Jul 2004 | A1 |
| 20040199241 | Gravett et al. | Oct 2004 | A1 |
| 20040265389 | Yui et al. | Dec 2004 | A1 |
| 20050101582 | Lyons et al. | May 2005 | A1 |
| 20050136122 | Sadozai et al. | Jun 2005 | A1 |
| 20050142152 | Leshchiner et al. | Jun 2005 | A1 |
| 20050181007 | Hunter et al. | Aug 2005 | A1 |
| 20050186261 | Avelar et al. | Aug 2005 | A1 |
| 20050186673 | Geistlich et al. | Aug 2005 | A1 |
| 20050226936 | Agcrup | Oct 2005 | A1 |
| 20050271729 | Wang | Dec 2005 | A1 |
| 20050287180 | Chen | Dec 2005 | A1 |
| 20060040894 | Hunter et al. | Feb 2006 | A1 |
| 20060095137 | Chung et al. | May 2006 | A1 |
| 20060122147 | Wohlrab et al. | Jun 2006 | A1 |
| 20060141049 | Lyons | Jun 2006 | A1 |
| 20060147483 | Chaouk et al. | Jul 2006 | A1 |
| 20060189516 | Yang et al. | Aug 2006 | A1 |
| 20060194758 | Lebreton et al. | Aug 2006 | A1 |
| 20060246137 | Hermitte et al. | Nov 2006 | A1 |
| 20060257488 | Hubbard | Nov 2006 | A1 |
| 20060286769 | Tsuchiya et al. | Dec 2006 | A1 |
| 20070026070 | Vonwiller et al. | Feb 2007 | A1 |
| 20070066816 | Tsai et al. | Mar 2007 | A1 |
| 20070077292 | Pinsky | Apr 2007 | A1 |
| 20070203095 | Sadozai et al. | Aug 2007 | A1 |
| 20070212385 | David | Sep 2007 | A1 |
| 20070224247 | Chudzik et al. | Sep 2007 | A1 |
| 20070224278 | Lyons et al. | Sep 2007 | A1 |
| 20070298005 | Thibault | Dec 2007 | A1 |
| 20080044476 | Lyons et al. | Feb 2008 | A1 |
| 20080057091 | Abdellaoui et al. | Mar 2008 | A1 |
| 20080089918 | Lebreton | Apr 2008 | A1 |
| 20080188416 | Bernstein | Aug 2008 | A1 |
| 20080193538 | Kitazono et al. | Aug 2008 | A1 |
| 20080200430 | Bitterman et al. | Aug 2008 | A1 |
| 20080207794 | Wright et al. | Aug 2008 | A1 |
| 20080241252 | Lyons et al. | Oct 2008 | A1 |
| 20080268051 | Hughes et al. | Oct 2008 | A1 |
| 20080274946 | Giampapa | Nov 2008 | A1 |
| 20080279806 | Cho | Nov 2008 | A1 |
| 20090018102 | Moutet et al. | Jan 2009 | A1 |
| 20090022808 | Champion et al. | Jan 2009 | A1 |
| 20090028817 | Niklason et al. | Jan 2009 | A1 |
| 20090036403 | Stroumpoulis et al. | Feb 2009 | A1 |
| 20090042834 | Karageozian et al. | Feb 2009 | A1 |
| 20090093755 | Schroeder et al. | Apr 2009 | A1 |
| 20090110671 | Miyata et al. | Apr 2009 | A1 |
| 20090110736 | Boutros | Apr 2009 | A1 |
| 20090143331 | Stoumpoulis et al. | Jun 2009 | A1 |
| 20090143348 | Tezel et al. | Jun 2009 | A1 |
| 20090148527 | Robinson et al. | Jun 2009 | A1 |
| 20090155314 | Tezel et al. | Jun 2009 | A1 |
| 20090155362 | Longin et al. | Jun 2009 | A1 |
| 20090169615 | Pinsky | Jul 2009 | A1 |
| 20090263447 | Asius et al. | Oct 2009 | A1 |
| 20090291986 | Pappas et al. | Nov 2009 | A1 |
| 20090297632 | Waugh | Dec 2009 | A1 |
| 20100004198 | Stroumpoulis et al. | Jan 2010 | A1 |
| 20100028437 | Lcbrcton | Feb 2010 | A1 |
| 20100035838 | Herber et al. | Feb 2010 | A1 |
| 20100041788 | Voigts et al. | Feb 2010 | A1 |
| 20100098764 | Stroumpoulis et al. | Apr 2010 | A1 |
| 20100098794 | Armand | Apr 2010 | A1 |
| 20100099623 | Schroeder et al. | Apr 2010 | A1 |
| 20100111919 | Abuzaina et al. | May 2010 | A1 |
| 20100136070 | Dobak et al. | Jun 2010 | A1 |
| 20100226988 | Lebreton | Sep 2010 | A1 |
| 20100255068 | Stroumpoulis et al. | Oct 2010 | A1 |
| 20100316683 | Piron et al. | Dec 2010 | A1 |
| 20110034684 | Yokokawa et al. | Feb 2011 | A1 |
| 20110118206 | Lebreton | May 2011 | A1 |
| 20120208890 | Gousse | Aug 2012 | A1 |
| 20130203696 | Njikang et al. | Aug 2013 | A1 |
| 20130210760 | Liu | Aug 2013 | A1 |
| 20140011990 | Lebreton | Jan 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| 949965 | Jun 1974 | CA |
| 104105474 | Oct 2014 | CN |
| 0273823 | Jul 1988 | EP |
| 0416250 | Mar 1991 | EP |
| 0416846 | Mar 1991 | EP |
| 1247522 | Oct 2002 | EP |
| 1398131 | Mar 2004 | EP |
| 1419792 | May 2004 | EP |
| 1532991 | May 2005 | EP |
| 1726299 | Nov 2006 | EP |
| 2236523 | Jun 2010 | EP |
| 2733427 | Oct 1996 | FR |
| 2759576 | Aug 1999 | FR |
| 2759577 | Aug 1999 | FR |
| 2780730 | Jan 2000 | FR |
| 2920000 | Feb 2009 | FR |
| 2924615 | Jun 2009 | FR |
| S 55-0153711 | Nov 1980 | JP |
| H 7-163655 | Jun 1995 | JP |
| 2007-063177 | Mar 2007 | JP |
| 2477138 | Mar 2013 | RU |
| WO 86000079 | Jan 1986 | WO |
| WO 86000912 | Feb 1986 | WO |
| WO 92000105 | Jan 1992 | WO |
| WO 92020349 | Nov 1992 | WO |
| WO 96033751 | Oct 1993 | WO |
| WO 94001468 | Jan 1994 | WO |
| WO 94002517 | Mar 1994 | WO |
| WO 9409795 | May 1994 | WO |
| WO 97004012 | Jun 1997 | WO |
| WO 98035639 | Aug 1998 | WO |
| WO 98035640 | Aug 1998 | WO |
| WO 00001428 | Jan 2000 | WO |
| WO 01079342 | Oct 2001 | WO |
| WO 02005753 | Jan 2002 | WO |
| WO 02006350 | Jan 2002 | WO |
| WO 02009792 | Feb 2002 | WO |
| WO 03007782 | Jan 2003 | WO |
| WO 02017713 | Mar 2003 | WO |
| WO 2004020473 | Mar 2004 | WO |
| WO 2004022603 | Mar 2004 | WO |
| WO 2004073759 | Sep 2004 | WO |
| WO 2004092222 | Oct 2004 | WO |
| WO 2004092223 | Oct 2004 | WO |
| WO 2005040224 | Jun 2005 | WO |
| WO 2005067944 | Jul 2005 | WO |
| WO 2005067994 | Jul 2005 | WO |
| WO 2005074913 | Aug 2005 | WO |
| WO 2005112888 | Dec 2005 | WO |
| WO 2006023645 | Mar 2006 | WO |
| WO 2006067608 | Jun 2006 | WO |
| WO 2007018124 | Feb 2007 | WO |
| WO 2007070617 | Jun 2007 | WO |
| WO 2007077399 | Jul 2007 | WO |
| WO 2007128923 | Nov 2007 | WO |
| WO 2008034176 | Mar 2008 | WO |
| WO 2008068297 | Jun 2008 | WO |
| WO 2008072230 | Jun 2008 | WO |
| WO 2008077172 | Jul 2008 | WO |
| WO 2008098019 | Aug 2008 | WO |
| WO 2008139122 | Nov 2008 | WO |
| WO 2008148967 | Dec 2008 | WO |
| WO 2008157608 | Dec 2008 | WO |
| WO 2009024719 | Feb 2009 | WO |
| WO 2009026158 | Feb 2009 | WO |
| WO 2009028764 | Mar 2009 | WO |
| WO 2009034559 | Mar 2009 | WO |
| WO 2009073437 | Jun 2009 | WO |
| WO 2010003797 | Jan 2010 | WO |
| WO 2010015900 | Feb 2010 | WO |
| WO 2010015901 | Feb 2010 | WO |
| WO 2010027471 | Mar 2010 | WO |
| WO 2010028025 | Mar 2010 | WO |
| WO 2010029344 | Mar 2010 | WO |
| WO 2010038771 | Apr 2010 | WO |
| WO 2010051641 | May 2010 | WO |
| WO 2010052430 | May 2010 | WO |
| WO 2010053918 | May 2010 | WO |
| WO 2010061005 | Jun 2010 | WO |
| WO 2013040242 | Mar 2013 | WO |
| Entry |
|---|
| Adams, “An Analysis of Clinical Studies of the Use of Crosslinked Hyaluronan, Hylan, in the Trcatmcnt of Ostcoarthritis.” The Journal of Rhcumatology, 1993, 16-18, 20 (39). |
| Aesthetic Buyers Guide, Juvederm Raises Standards, 2007, 1, 4-7; www.miinews.com. |
| Albano et al., “Hydroxyethyl Radicals in Ethanol Hepatotoxicity,” Frontiers in Bioscience, 1999, 533-540, 4. |
| Allemann, “Hyaluronic Acid Gel (Juvederm) Preparations in the Treatment of Facial Wrinklcs and Folds,” Clinical Intcrvcntions in Aging, 2008, 629-634, 3 (4). |
| Alsoufi, New and Innovative Developments in Hyaluronic Acid Fillers for Lip Enhancement and Contouring, European Dermaltology, 2011, vol. 5, pp. 50-53. |
| Antunes et al., “Efficacy of Intrarectal Lidocaine Hydrochloride Gel for Pain Control in Patients Undergoing Transrectal Prostate Biopsy,” Clinical Urology, 2004, 380-383, 30. |
| Atanassoff et al., “The Effect of Intradermal Administration of Lidocaine and Morphine on the Response to Thermal Stimulation,” Anesth Analg, 1997, 1340-1343, 84. |
| Baumann et al.,“Comparison of Smooth-Gel Hyaluronic Acid Dermal Fillers with Cross-linked Bovine Collagen: A Multicenter, Double-Masked, Randomized, Within-Subject Study,” Dermatologic Surgery, 2007, S128-135, 33 (2). |
| Beasley et al., “Hyaluronic Acid Fillers: A Comprehensive Review,” Facial Plastic Surgery, 2009, 86-94, 25 (2). |
| Beer, “Dermal Fillers and Combinations of Fillers for Facial Rejuvenation,” Dermatologic Clin, 2009, 427-432, 27 (4). |
| Belda et al., “Hyaluronic Acid Combined With Mannitol to Improve Protection Against Free-Radical Endothelial Damage: Experimental Model,” J Cataract Refract Surg, 2005, 1213-1218, 31. |
| Bircher et al., “Delayed-type Hypersensitivity to Subcutaneous Lidocaine With Tolerance to Articaine: Confirmation by In Vivo and In Vitro Tests,” Contact Dermatitis, 1996, 387-389, 34. |
| Bluel et al., “Evaluation of Reconstituted Collagen Tape as a Model for Chemically Modified Soft Tissues,” Biomat. Med. Dev. Art. Org., 1981, 37-46, 9 (1). |
| Buck, “Injectable Fillers for Facial Rejuvenation: A Review,” Journal of Plastic, Reconstructive & Aesthetic Surgery, 2009, 11-18, 62. |
| Capozzi et al., “Distant Migration of Silicone Gel From a Ruptured Breast Implant,” Silicone Gel Migration, 1978, 302-3, 62 (2). |
| Carlin, et al., “Effect of Anti-Inflammatory Drugs on Xanthine Oxidase and Xanthine Oxidase Induced Depolymerization of Hyaluronic Acid,” Agents and Actions, 1985, 377-384, 16 (5). |
| Carruthers et al., “Tire Science and Art of Dermal Fillers for Soft-Tissue Augmentation,” Journal of Drugs in Dermatology, 2009, 335-350, 8 (4). |
| Cavallini et al., “Skin Quality Improvement With VYC-12, a New Injectable Hyaluronic Acid: Objective Results Using Digital Analysis,” Dermatol Surg, 2019, 45:1598-1604. |
| Champion et al., “Role of Target Geometry in Phagocytosis,” Proc. Nat. Acad. Sci., 2006, 4930-4934, 103 (13). |
| Chee, “Estimation of Molecular Weight Averages from Intrinsic Viscosity,” Journal of Applied Polymer Science, 1985, 1359-1360, vol. 30, John Wiley & Sons, Inc. |
| Chin et al., “Allergic Hypersensitivity to Lidocaine Hydrochloride,” International Society of Tropical Dermatology, 1980, 147-148. |
| Chvapil, “Collagen Sponge: Theory and Practice of Medical Applications,” J. Biomed. Mater. Res., 1977, 721-741, 11. |
| Clark et al., “The Influence of Triamcinolone Acetonide on Joint Stiffness in the Rat,” The Journal of Bone and Joint Surgery, 1971, 1409-1414, 53A (7). |
| Cohen et al., “Organization and Adhesive Properties of the Hyaluronan Pericellular Coat of Chondrocytes and Epithelial Cells,” Biophysical Journal, 2003, 1996-2005, 85. |
| Cui et al., “The Comparison of Physicochemical Properties of Four Cross-linked Sodium Hyaluronate Gels With Different Cross-linking Agents,” Advanced Materials Research, 2012, 1506-1512, 396-398. |
| Decision from the Opposition Division for European Patent No. EP-B-2 289 945, dated Jun. 30, 2017. |
| Decision T1250/10-3.3.03 de la Chambre de Recourse 3.3.03 dated Nov. 5, 2012. |
| Declaration of Dr. Sebastien Pierre to the EPO in the matter of European Patent: 2289945, Proprietor: Allergan Industrie, dated Jul. 7, 2016. |
| Deland, “Intrathecal Toxicity Studies with Benzyl Alcohol,” Toxicology and Applied Pharmacology, 1973, 153-6, 25, Academic Press, Inc. |
| Desai et al., “Molecular Weight of Heparin Using 13C Nuclear Magnetic Resonance Spectroscopy,” J Pharm Sci., 1995, 212-5, 84 (2). |
| EP 2289945 Counterstatements, Dec. 21, 2015, EP. |
| EP 2289945 Notification of Opposition, Dec. 16, 2015, EP. |
| Europcan Pharmacopocia 5th Ed., Main vol. 5.0, 2005 with Supplements 5.1 and 5.2, Sodium Hyaluronate. |
| Eyre et al., “Collagen Cross-Links,” Top Curr Chem, 2005, 207-229, 247, Springer-Verlag, Berlin Heidelberg. |
| Falcone et al., “Crosslinked Hyaluronic Acid Dermal Fillers: A Comparison of Rheological Properties,” Journal of Biomedical Materials Research, 2008, 264-271, 87 (1). |
| Falcone et al., “Temporary Polysaccharide Dermal Fillers: A Model for Persistence Based on Physical Properties”, Dermatologic Surgery, 2009, 1238-1243, 35 (8). |
| Farley et al., “Diluting Lidocaine and Mepivacaine in Balanced Salt Solution Reduces the Pain of Intradermal Injection,” Regional Anesthesia, 1994, 48-51, 19 (1). |
| Frati et al.,“Degradation of Hyaluronic Acid by Photosensitized Riboflavin In Vitro. Modulation of the Effect by Transition Metals, Radical Quenchers, and Metal Chelators,” Free Radical Biology Medicine, 1996, 1139-1144, 22 (7). |
| Fujinaga et al., “Reproductive and Teratogenic Effects of Lidocaine in Sprague-Dawley Rats,” Anesthesiology, 1986, 626-632, 65. |
| Gammaitoni et al., “Pharmacokinetics and Safety of Continuously Applied Lidocaine Patches 5%,” Am J Health Syst Pharm, 2002, 2215-2220, 59. |
| Ginshicel Mh, Hydroxy Propyl Methyl Cellulose, Retrieved on Nov. 12, 2008 http://www.ginshicel.cn/MHPC.html, 2007, p. 1-3, 2 (3). |
| Gold, “Use of Hyaluronic Acid Fillers for the Treatment of the Aging Face,” Clin. Interventions Aging, 2007, 369-376, 2 (3). |
| Goldberg, “Breakthroughs in US dermal fillers for facial soft-tissue augmentation,” Journal of Cosmetic and Laser Therapy, 2009, 240-247, 11, Informa UK Ltd. |
| Gomis et al., “Effects of Different Molecular Weight Elastoviscous Hyaluronan Solutions on Articular Nociceptive Afferents,” Arthritis and Rheumatism, Jan. 2004, 314-326, 50(1). |
| Graefe et al., “Sensitive and Specific Photometric Determination of Mannitol,” Clin Chem Lab Med, 2003, 1049-1055, 41 (8). |
| Grecomoro et al., “Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo,” Pharmatherapeutica, 1987, 137-141, 5 (2). |
| Grillo et al., “Thermal Reconstitution of Collagen From Solution and the Response to Its Heterologous Implantation,” JSR, 1962, 69-82, 2 (1). |
| Harding et al., “Molecular Weight Determination of Polysaccharides,” Advances in Carbohydrate Analysis, 1991, 63-144, vol. 1, JAI Press Ltd. |
| Hassan et al., “Effects of Adjuvants to Local Anaesthetics on Their Duration. III. Experimental Studies of Hyaluronic Acid,” Acta Anaesthesiol Scand., 1985, 1, 29 (4). |
| Hayashibara, “AA2G,” Sep. 23, 2007, Retrieved on Jan. 17, 2012, http://web.archive.org/web/20070923072010/http://www.hayashibara-intl.com-/cosmetics/aa2g.html. |
| Helliwell, “Use of an objective measure of articular stiffness to record changes in finger joints aftcr intra-articular injcction of corticostcroid,” Annals of Rhcumatic Discascs, 1997, 71-73, 56. |
| Hertzberger-Ten et al., “Intra-articular steroids in pauciarticular juvenile chronic arthritis, type 1,” European Journal of Pediatrics, 1991, 170-172, 150. |
| Hetherington et al., “Potential for Patient Harm from Intrathecal Administration of Preserved Solutions,” Med J Aust., 2000, 1, 173(3). |
| Hurst, “Adhesive Arachnoiditis and Vascular Blockage Caused by Detergents and Other Chemical Irritants: An Experimental Study,” J Path. Bact., 1955, 167, 70. |
| Intramed (PTY) Ltd, Intramed Mannitol 20% m/v Infusion, Package Insert, Jan. 1979, 4 pages, 12-214/8-94, ZA. |
| Jones et al., “Intra-articular hyaluronic acid compared to intra-articular triamcinolone hcxacctonidc in inflammatory kncc ostcoarthritis,” Ostcoarthritis and Cartilagc, 1995, 269-273, 3. |
| Juvederm Volux, Product Insert, Jul. 26, 2018, 65 pages. |
| Kablik et al., “Comparative Physical Properties of Hyaluronic Acid Dermal Fillers,” Dermatology Surgery, 2009, 302-312, 35. |
| Kasten, “Volumisicrung dcs Mittclgcsichts,” Apr. 2014, retrieved from http://www.zwp-online.info/archiv/pub/sim/fa/2014/fa0414/fa0414_10_14_kasten.pdf, 5 pages. |
| Klein, “Skin Filling Collagen and Other Injectables of the Skin,” Fundamentals of Cosmetic Surgery, 2001, 491-508, 3 (19). |
| Kogan et al., “Hyaluronic Acid: A Biopolymer with Versatile Physico-Chemical and Biological Properties,” Handbook of Polymer Research: Monomers, Oligomers, Polymers and Composites, 2007, 415-416, Chapter 31, Nova Science Publilshers, Inc. |
| Kopp et al., “The Short-term Effect of Intra-articular Injections of Sodium Hyaluronate and Corticosteroid on Temporomandibular Joint Pain and Dysfunction,” Journal of Oral and Maxillofacial Surgery, 1985, 429-435, 43. |
| Kulicke et al., “Visco-Elastic Properties of Sodium Hyaluronate Solutions,” Institute for Technical and Macromolecular Chemistry, 2008, 585-587, DE. |
| Laeschke, “Biocompatibility of Microparticles Into Soft Tissue Fillers,” Semin Cutan Med Surg, 2004, 214-217, 23. |
| Lamar et al., “Antifibrosis Effect of Novel Gels in Anterior Ciliary Sclerotomy (ACS),” 2002, 1 Page, The Association for Research in Vision and Ophthalmology, Inc. |
| Levy et al., “Lidocaine Hypersensitivity After Subconjunctival Injection”, Can J Ophthalmol, 2006, 204-206, 41. |
| Lindvall et al., “Influence of Various Compounds on the Degradation of Hyaluronic Acid by a Myeloperoxidase System”, Chemico-Biological Interactions, 1994, 1-12, 90. |
| Lupo, “Hyaluronic Acid Fillers in Facial Rejuvenation,” Seminars in Cutaneous Medicine and Surgcry, 2006, 122-126, 25. |
| Mackley et al., “Delayed-Type Hypersensitivity to Lidocaine,” Arch Dermatol, 2003, 343-346, 139. |
| Mancinelli et al., “Intramuscular High-dose Triamcinolone Acetonide in the Treatment of Severe Chronic Asthma,” West J Med, 1997, 322-329, 167 (5). |
| Matsumoto ct al., “Reducing the Discomfort of Lidocainc Administration Through pH Buffering,” Journal of Vascular and Interventional Radiology, 1994, 171-175, 5 (1). |
| Mccarty et al., “Inflammatory Reaction after Intrasynovial Injection of Microcrystalline Adrenocorticosteroid Esters,” Arthritis and Rheumatism, 1964, 359-367, 7 (4). |
| Mccleland et al., “Evaluation of Artecoll Polymethylmethacrylate Implant for Soft-Tissue Augmentation: Biocompatibility and Chemical Characterization,” Plastic & Reconstructive Surgery, 1997, 1466-1474, 100 (6). |
| Mcpherson et al., “Development and Biochemical Characterization of Injectable Collagen,” Journal of Dermatol Surg Oncol, 1988, 13-20, 14 (Suppl 1) 7. |
| Millay et al., “Vasoconstrictors in Facial Plastic Surgery,” Arch Otolaryngol Head Neck Surg., 1991, 160-163, 117. |
| Ncws Rclcasc, Mandom Corporation, May 31, 2010, 9 pagcs including English languagc translation. |
| Orvisky et al., “High-molecular-weight Hyaluronan—a Valuable Tool in Testing the Antioxidative Activity of Amphiphilic Drugs Stobadine and Vinpocetine,” Journal of Pharm. Biomed. Anal., 1997, 419-424, 16. |
| Osmitrol (generic name Mannitol), Official FDA Information, side effects and uses, http://www.drugs.com/pro/osmitrol.html, 2010, 10 Pages. |
| Park et al., “Biological Characterization of EDC-Crosslinked Collagen-Hyaluronic Acid Matrix in Dermal Tissue Restoration,” Biomaterials, 2003, 1631-1641, 24. |
| Park et al., “Characterization of Porous Collagen/Hyaluronic Acid Scaffold Modified by 1-Ethyl-3-(3-Dimethylaminopropyl)Carbodiimide Cross-Linking,” Biomaterials, 2002, 1205-1212, 23. |
| Pierre, et al., “Basics of Dermal Filler Rheology,” Dermatol Surg, 2015, vol. 41, pp. S120-S126. |
| Powell, “Stability of Lidocaine in Aqueous Solution: Effect of Temperature, pH, Buffer, and Metal Ions on Amide Hydrolysis,” Pharmaceutical Research, 1987, 42-45, 4 (1). |
| Prestwich, “Evaluating Drug Efficacy and Toxicology in Three Dimensions: Using Synthetic Extracellular Matrices in Drug Discovery,” Accounts of Chemical Research, Jan. 2008, 139-148, 41(1). |
| Ramos-E-Silva et al., “STYLAGE: a range of hyaluronic acid dermal fillers containing mannitol. Physical properties and review of the literature,” 2013, Clinical, Cosmetic and Investigational Dermatology, pp. 257-261. |
| Rehakova et al., “Properties of Collagen and Hyaluronic Acid Composite Materials and Their Modification by Chemical Crosslinking,” Journal of Biomedical Materials Research, 1996, 369-372, 30, US. |
| Remington's Pharmaceutical Sciences, 1980, 16th Edition, Mack Publishing Company, Easton, Pennsylvania. |
| Response to Summons to attend Oral Proceedings under Rule 115(1) EPC of Nov. 10, 2016, Opposition against EP 2289945 Proprietor: Allergan Idustrie Opponent: Merz Pharma GmbH & Co. KGaA, Dated Apr. 26, 2017. |
| Restyane Silk—Summary of Safety and Effectiveness Data, PMA No. P040024/s72, Jun. 2014, retrieved from https://www.accessdata.fda.gov/cdrh_docs/pdf4/P040024S072b.pdf, 33 pages. |
| Rosenblatt et al., “Tire Effect of Collagen Fiber Size Distribution on the Release Rate of Proteins From Collagen Matrices by Diffusion,” J Controlled Release, 1989, 195-203, 9. |
| Rosenblatt. et al., “Chain Rigidity and Diffusional Release in Biopolymer Gels,” Controlled Release Society, 1993, 264-265, 20. |
| Sannino et al., “Crosslinking of Cellulose Derivatives and Hyaluronic Acid With Water-Solublc Carbodiimidc,” Polymcr, 2005, 11206-11212, 46. |
| Schiiling et al., Is Human Height Bimodal, The American Statistician, 2002, 223-229, 56 (3), US. |
| Sculptra® (injectable poly-L-lactic acid) Directions for Use, Product Insert, Jul. 2004, 12 Pages, Dermik Laboratories. |
| Segura et al., “Crosslinked Hyaluronic Acid Hydrogels: A Strategy to Functionalize and Pattern,” Biomaterials, 2005, 359-371, 26 (4). |
| Selvi et al., “Arthritis Induced by Corticosteroid Crystals,” The Journal of Rheumatology, 2004, 622, 31 (3). |
| Serban et al., “Modular Extracellular Matrices: Solutions for the Puzzle,” Methods, 2008, 93-98, 45 (1). |
| Shu et al, “Synthesis and evaluation of injectable, in situ crosslinkable synthetic extracellular matrices for tissue engineering,” Journal of Biomedical Materials Research, 2006, 902-912, 79A. |
| Silver et al., “Physical Properties of Hyaluronic Acid and Hydroxypropylmethylcellulose in Solution: Evaluation of Coating Ability,” Journal of Applied Biomaterials, 1994, 89-98, 5. |
| Skardal et al., “Bioprinting Vessel-Like Constructs Using Hyaluronan Hydrogels Crosslinked With Tetrahedral Polyethylene Glycol Tetracrylates,” Biomaterials, 2010, 6173-6181, 31. |
| Smith et al., “Five Percent Lidocaine Cream Applied Simultaneously to the Skin and Mucosa of the Lips Creates Excellent Anesthesia for Filler Injections,” Dermatol Surg, 2005, 1635-1637, 31. |
| Tezel et al., “The science of hyaluronic acid dermal fillers,” Journal of Cosmetic and Laser Therapy, 2008, 35-42, 10. |
| The European Aesthetic Guide, Spring 2011, Dermal Filler Comparison Chart, pp. 89-99. |
| “Varioderm es,” Dec. 2011, retrieved from http://www.circugiadeavanzada.com/pdf/varioderm/pdf, 16 pages. |
| Visiol, TRB Chemedica Ophthalmic Line, Product Info, May 2014, p. 1-2, Geneva, CH. |
| Visiol, Viscoelstic Gel for Use in Ocular Surgery, http://www.trbchemedica.com/index.php/option=com_content&tas, 2010, 1 Page. |
| Wagner, “The Mark-Houwink-Sakurada Equation for the Viscosity of Linear Polyethylene,” J. Phys. Chem. Ref. Data, 1985, 611-617, vol. 14, No. 2. |
| Wahl, “European Evaluation of a New Hyaluronic Acid Filler Incorporating Lidocaine,” Journal of Cosmetic Dermatology, 2008, 298-303, 7. |
| Waraszkiewicz et al., “Stability-Indicating High-Performance Liquid Chromatographic Analysis of Lidocaine Hydrochloride and Lidocaine Hydrochloride with Epinephrine Injcctable Solutions,” Journal of Pharmaceutical Scicnccs, 1981, 1215-1218, 70 (11). |
| Weidmann, “New Hyaluronic Acid Filler for Subdermal and Long-lasting Volume Restoration of the Face,” European Dermatology, 2009, 65-68. |
| Weidmann, “Varioderm—eine Innovation im Bereich der Hyaluronsauren,” Jun. 2007. |
| Xia et al., “Comparison of Effects of Lidocaine Hydrochloride, Buffered Lidocaine, Diphenhydramine, and Normal Saline After Intradermal Injection,” Journal of Clinical Anesthesia, 2002, 339-343, 14. |
| Yeom et al., “Effect of Cross-Linking Reagents for Hyaluronic Acid Hydrogel Dermal Fillers on Tissue Augmentation and Regeneration,” Bioconjugate Chemistry, 2010, 240-247, 21, American Chemical Society. |
| Yui et al., “Inflammation Responsive Degradation of Crosslinked Hyaluronic Acid Gels,” Journal of Controlled Release, 1992, 105-116, 26. |
| Yui et al., “Photo-Responsive Degradation of Heterogeneous Hydrogels Comprising Crosslinked Hyaluronic Acid and Lipid Microspheres for Temporal Drug Delivery,” Journal of Controlled Release, 1993, 141-145, 26. |
| Yun et al., “Hyaluronan Microspheres for Sustained Gene Delivery and Site-Specific Targeting,” Biomaterials, 2004, 147-157, 25, US. |
| Zheng et al., “In Situ Crosslinkable Hyaluronan Hydrogels for Tissue Engineering,” Biomaterials, 2004, 1339-1348, 25. |
| Zulian et al., “Triamcinolone Acetonide and Hexacetonide Intra-Articular Treatment of Symmetrical Joints in Juvenile Idiopathic Arthritis: A Double-Blind Trial,” Rheumatology, 2004, 1288-1291, 43. |
| EP 16704566.5 3rd Party Observations, dated Sep. 4, 2020, 30 pages. |
| “Mark-Houwink-Gleichung,” from https://de.wikipedia.org/wiki/Mark-Houwink-Gleichung, Dec. 2017, 3 pages including English language translation. |
| “Molmassenverteilung,” from https://de.wikipedia.org/wiki/Molmassenverteilung, Dec. 2017, 9 pages including English language translation. |
| Carruthers et al., “Volumizing with a 20-mg/ml Smooth, Highly Cohesive, Viscous Hyaluronic Acid Filler and its Role in Facial Rejuvenation Therapy,” Dermatologic Surgery, 2010, vol. 36, pp. 1886-1892. |
| “Molecular Weight,” The Univerity of Southern Mississippi, 2005, 5 pages. |
| Math Review, Educational Testing Service, 2017, from https://ets.org/s/gre/pdf/gre_math_review.pdf, 198 pages. |
| Wikipedia page on “Educational Testing Service,” from https://en.wikipedia.org/wiki/Educational_Testing_Service, last edited Nov. 2020. |
| Number | Date | Country | |
|---|---|---|---|
| 20200345612 A1 | Nov 2020 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15549990 | US | |
| Child | 16877315 | US |
